Decreased NK Cell FcRγ in HIV-1 Infected Individuals Receiving Combination Antiretroviral Therapy: a Cross Sectional Study

Edwin Leansyah1,2, Jingling Zhou1, Geza Paukovics1, Sharon R. Lewin1,2,3, Suzanne M. Crowe1,2,3, Anthony Jaworowski1,2*

1 Centre for Virology, The Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia, 2 Department of Medicine, Monash University, Melbourne, Australia, 3 Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia

Abstract

Background: FcRγ is an immunoreceptor tyrosine-based activation motif (ITAM)-signalling protein essential for immunoreceptor signaling and monocyte, macrophage and NK cell function. Previous study from our laboratory showed that FcRγ is down-regulated in HIV-infected macrophages in vitro. FcRγ expression in immune cells present in HIV-infected individuals is unknown.

Methodology/Principal Findings: We compared FcRγ expression in peripheral blood mononuclear cells isolated from HIV-1-infected individuals receiving combination antiretroviral therapy and healthy, HIV-1-uninfected individuals. FcRγ mRNA and protein levels were measured using quantitative real-time PCR and immunoblotting, respectively. CD56+ CD94+ lymphocytes isolated from blood of HIV-1 infected individuals had reduced FcRγ protein expression compared to HIV-uninfected individuals (decrease = 76.8%, n = 18 and n = 12 respectively, p = 0.0036). In a second group of patients, highly purified NK cells had reduced FcRγ protein expression compared to uninfected controls (decrease = 50.2%, n = 9 and n = 8 respectively, p = 0.021). Decreased FcRγ expression in CD56+CD94+ lymphocytes was associated with reduced mRNA (51.7%, p = 0.021) but this was not observed for the smaller group of patients analysed for NK cell expression (p = 0.36).

Conclusion/Significance: These data suggest biochemical defects in ITAM-dependent signalling within NK cells in HIV-infected individuals which is present in the context of treatment with combination antiretroviral therapy.

Introduction

HIV-1 infection, like other chronic inflammatory diseases, is associated with immune activation, which is an important independent predictor of HIV-1 disease progression [1,2]. Immune activation may be caused by a combination of persistent HIV-1 replication and innate immune activation via gut-associated pathogen, associated with loss of gut-associated lymphoid tissue (GALT) [3]. Immune activation markers on leukocytes and in plasma may persist even after initiation of combination antiretroviral therapy (cART) [4,5,6]. The observation that GALT is not as rapidly restored as peripheral blood CD4+ T cell counts following cART [7,8] suggests that immune activation due to elevated bacterial products and its downstream consequences also persist after viral suppression, which is indicated by elevated endotoxin levels in plasma even after 48 weeks of cART [3].

Chronic inflammatory diseases are characterised by defective immunoreceptor signaling mediated by immunoreceptor tyrosine-based activation motif (ITAM) domain-containing adaptor proteins [reviewed in [9]]. The only reports of ITAM protein expression in the context of HIV infection have been older observations that HIV-1 infection in patients not receiving cART was associated with decreased expression of TCRζ (an ITAM-signalling protein that mediates T-cell receptor signaling) in bystander cells that are not necessarily infected by HIV-1, including NK and CD8+ T cells [10,11,12]. Limited data suggest that expression of TCRζ is restored by cART [10].

Fc receptor common γ-chain (FcγRγ) is the most widespread ITAM-signalling protein. It is broadly expressed in haematopoietic cells including monocytes, macrophages, NK cells and effector CD4+ T cells. It is promiscuously associated with, and transduces signals from, a broad range of immunoreceptors, including FcεR, FcγR, FcγR, NKP46 and TCR [13]. Studies using NK cells from FcγR knockout mice show that this protein is absolutely required for NK cell mediated cytotoxicity [14]. We have previously shown that FcγR expression is decreased in human monocyte-derived macrophages (MDM) infected with HIV-1 in vitro, leading to...
impaired FcγR-mediated phagocytosis in this model of tissue macrophages [15,16]. This inhibition is not restricted to HIV-1-infected cells [16] suggesting that HIV-1 infection reduces FcγR expression by a bystander mechanism. Whether HIV reduces FcγR in other cell types is not known. There have been no studies examining expression of FcγR in chronic inflammatory diseases, and in the context of HIV-1 infection in particular. Given the importance of FcγR in signaling from a wide variety of immunoreceptors, and our *in vitro* observations that HIV-1 infection causes a bystander-mediated decrease in FcγR expression, we examined its expression in peripheral blood mononuclear cells from a cohort of HIV-1 infected patients receiving cART.

**Methods**

**Ethics Statement**

This study is approved by The Alfred Human Research Ethics Committee (Project 36/02) with a protocol that conforms to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000).

**Objectives**

To measure FcγR expression in peripheral blood cells from a current cohort of HIV-infected and control, HIV-uninfected subjects. We hypothesise that HIV-infection is associated with decreased expression of FcγR in the context of treatment with combination antiretroviral therapy (cART).

**Participants**

All HIV-infected individuals were recruited from the Alfred Hospital Infectious Diseases Outpatient Clinic (Melbourne, Australia) and were receiving cART with no history of, or current, AIDS-defining illness at recruitment. Blood samples were collected by venepuncture into EDTA containing blood collection tubes with informed written consent. Gender-matched, healthy HIV-uninfected individuals were recruited via advertisement within the Burnet Institute (Melbourne, Australia) and blood was collected with ethics approval and written informed consent by venepuncture into EDTA tubes.

**Antibodies**

Mouse anti-GAPDH mAb (clone 6C5) was from Santa Cruz Biotechnology, and rabbit anti-FcγR antisera was from Dr. Bruce Wines (Burnet Institute, Melbourne, Australia). Mouse fluorochrome-conjugated antibodies CD3-FITC, CD14-PE, CD14-FTTC, CD16-PerCP-Cy5.5, CD19-FITC, CD56-APC, CD94-APC and isotype matched IgG1-FITC, -PE, -PerCP-Cy5.5 and -APC were from BD Biosciences. Goat anti-rabbit Alexa Fluor® 680 and goat anti-mouse IRDye® 800 were from Molecular Probes and Rockland Immunochemicals, respectively.

**Cell Isolation**

Peripheral blood mononuclear cells (PBMC) were labeled with 25 μg/ml anti-CD3-FITC and anti-CD14-PE, or 37.5 μg/ml of anti-CD56-APC and anti-CD94-APC or with corresponding mouse IgG1 isotype control antibodies. Cells were washed twice in cold FACS sorting buffer (Ca²⁺,Mg²⁺ free PBS, 2 mM EDTA, 1% newborn calf serum (HyClone)) and resuspended at 4x10⁶ cells/ml. CD14⁺ monocytes, CD3⁻ CD56⁺/CD19⁻ NK cells, and CD3⁺ T lymphocytes were isolated using a high-speed cell sorter (FACSARia™, BD Biosciences) under PC3 containment conditions. In selected experiments, PBMC were stained with 25 μg/ml each of anti-CD3-FTTC, anti-CD14-FTTC and anti-CD19-FTTC, 37.5 μg/ml of each anti-CD16-PerCP-Cy5.5 and anti-CD56-APC in combination. NK cells (gated on CD3⁻ / CD14⁻ /CD19⁻ cells in the lymphocyte region) were subsequently sorted into CD56dim CD16⁺ and CD56bright CD16⁻ subsets. Sorted cells were washed twice in cold Ca²⁺,Mg²⁺-free PBS, and 1x10⁶ cells from each population were lysed with RNA lysis/binding buffer [16]. Remaining cells were lysed with 200 μl cold Triton lysis buffer (TLB) [16]. TLB extracts were incubated at 4°C for 10 min and clarified at 20,000 g for 10 min at 4°C.

**Measurement of FcγR and TCRγ mRNA Expression**

FcγR mRNA was measured by quantitative real-time PCR (Q-PCR) as described [16]. TCRγ (GenBank accession NM199035) mRNA was measured under identical conditions but using the forward primer 5'-TCAGCCCTCTGCCTGCAGCCA-3' and reverse primer 3'-CTCAGCTTAGGGCTCAGCCA-3'. Both FcγR and TCRγ mRNA levels were quantified using the comparative threshold method, with GAPDH mRNA as an internal standard. FcγR was co-immunoprecipitated from cellular extracts with GAPDH as an internal control then immunoprecipitates were resolved by SDS PAGE. Blots were probed with rabbit anti-FcγR plus mouse anti-GAPDH then goat anti-rabbit Alexa Fluor® 680 plus goat anti-mouse IRDye® 800. Fluorescence in both channels was quantified using a LI-COR Odyssey infrared (IR) imager (LI-COR Biosciences) and expressed as a ratio of FcγR/GAPDH fluorescence.

**Results**

RNA extracts prepared from a single HIV-uninfected donor were analysed by PCR. FcγR mRNA was expressed at high levels in monocytes and moderate levels in NK cells, but low levels in T lymphocytes (Figure 1A–C). Within CD56/CD94-positive cells most of the expression was found within CD3⁻ NK cells and only minor expression within the CD3⁺ population. TCRγ was not detected in monocytes (Figure 1B,C). Protein analysis also showed a lack of FcγR expression in T lymphocytes either within the whole CD3⁺ population or specifically within CD56⁺/CD94⁺ T lymphocytes (Figure 1C). FcγR mRNA expression was similar in both the CD56⁺/CD16⁻ and CD56⁺/CD16⁺ NK subsets (Figure 1D,E). In the following experiments, FcγR expression was therefore measured in monocyte and NK cell lysates and TCRγ expression in T cell and NK cell lysates.

Monocytes and T lymphocytes were purified from blood sampled from eighteen HIV-infected patients (subjects 1–18, Table 1) and twelve healthy, HIV-uninfected individuals. All patients received cART at time of recruitment and most (78%) had viral load (VL)<50 copies/ml. Monocytes from HIV-infected individuals showed a small but significant increase in FcγR mRNA (median HIV⁺=23.30, HIV⁻=17.10, p=0.037, Figure 2A) compared to that from uninfected controls, although similar levels of FcγR protein were expressed (median HIV⁺=6.155, HIV⁻=6.465, p=0.88, Figure 2B). TCRγ mRNA expression in T lymphocytes was unchanged in these patients (median HIV⁺=3.95, HIV⁻=5.60, p=0.21, Figure 3A) consistent with previous findings that TCRγ expression is restored following cART [10]. Analysis of CD56⁺/CD94⁺ cells from the sorted populations (consisting of NK cells plus CD56⁺/CD94⁺ lympho-
cytes) also showed similar levels of TCRf expression (median HIV+ = 10.9, HIV− = 12.1, p = 0.74, Figure 3B). When FcRc expression was compared, however, the CD56+/CD94+ cell population showed a considerable decrease in both FcRc mRNA expression (median HIV+ = 7.2, HIV− = 14.9, p = 0.021, Figure 4A) and protein expression (median HIV+ = 1.040, HIV− = 4.490, p = 0.0036, Figure 4B). Since within this mixed population only the CD3− CD56+/CD94+ NK cell fraction expressed appreciable FcRγ (Figure 1B,C) this suggests that decreased FcRγ expression in HIV-infected individuals occurs in NK cells. To address this, a further nine HIV-infected patients (subjects 19–27, Table 1) and eight control subjects were enrolled and PBMC prepared from these individuals were specifically sorted to obtain highly purified monocytes and NK cells. There was a 50% decrease in FcRγ protein expression (median protein HIV+ = 2.061, HIV− = 4.139, p = 0.021, Figure 3A) but FcRγ mRNA expression was unchanged (median RNA HIV+ = 20.30, HIV− = 26.30, p = 0.36, Figure 5B) in NK cells from HIV-infected individuals. Levels of TCRγ mRNA in NK cells were equivalent in the two populations (median mRNA HIV+ = 8.80, HIV− = 17.35, p = 0.34, Figure 5C) again consistent with previous reports [10]. There was no significant correlation between decreased FcRγ protein levels in NK cells with either nadir or current CD4 counts (r = −0.22, p = 0.58 and r = 0.18, p = 0.64 respectively) from these HIV-1-infected individuals (n = 9, patients 19–27). Since only one patient (patient 22, Table 1) had high level of viremia, determining whether levels of FcRγ correlated with viral load was not possible. However since five of the nine patients examined had an undetectable viral load, it is not likely that viremia is a significant contributor to reduced NK cell FcRγ expression in the context of HIV infection.

Chronic HIV-1 infection is associated with a progressive decline in NK cell numbers and function [17]. We therefore examined the potential association between FcRγ expression and NK cell proportion in peripheral blood mononuclear cells. Unexpectedly, there was a strong negative correlation between FcRγ protein levels and the proportion of NK cells in HIV-infected individuals (Spearman’s r = −0.71, p = 0.037, Figure 6A) although the proportion of NK cells was not significantly different in this cohort of cART treated patients compared to uninfected control subjects (Figure 6B) in agreement with results from others [18]. Similarly, we observed a negative correlation between FcRγ mRNA concentration and proportion of NK cells in these individuals (r² = 0.52, p = 0.028, data not shown). There was no...
Table 1. Clinical details of HIV-1 infected patients used in this study.

| Donor | CD4 (cells/µl) | Nadir CD4 (cells/µl) | Viral load (RNA copies/ml) | Current therapy regimen$^1$ |
|-------|----------------|----------------------|---------------------------|-----------------------------|
| 1     | 640            | 40                   | 8300                      | 3TC, TDF, ATV, T20,         |
| 2     | 396            | 143                  | <50                       | FTC, TDF, FPV               |
| 3     | 57             | 54                   | 6750                      | 3TC, ABC, FPV               |
| 4     | 599            | 50                   | <50                       | 3TC, AZT, ATV               |
| 5     | 178            | 140                  | <50                       | FTC, TDF, NVP,              |
| 6     | 381            | 0                    | 1600                      | DRV, ETV, TDF, RTV          |
| 7     | 243            | 72                   | >100,000                  | 3TC, D4T, TDF, DRV, T20     |
| 8     | 830            | 110                  | <50                       | 3TC, ABC, LPV               |
| 9     | 352            | 54                   | <50                       | 3TC, ABC, ATV               |
| 10    | 430            | 0                    | <50                       | FTC, TDF, LPV               |
| 11    | 598            | 230                  | <50                       | FTC, TDF, RGV, T20          |
| 12    | 728            | 231                  | <50                       | 3TC, ABC, NVP               |
| 13    | 365            | 258                  | <50                       | FTC, TDF, EFV               |
| 14    | 381            | 381                  | <50                       | 3TC, ABC, NVP               |
| 15    | 891            | 315                  | <50                       | 3TC, AZT, NVP               |
| 16    | 639            | 252                  | <50                       | FTC, TDF, NVP,              |
| 17    | 1205           | 308                  | <50                       | FTC, TDF, EPV               |
| 18    | 1176           | 230                  | <50                       | FTC, TDF, NVP               |
| 19    | 255            | 149                  | <50                       | 3TC, TDF, NVP               |
| 20    | 275            | 67                   | 1700                      | FTC, TDF, EPV               |
| 21    | 720            | 97                   | <50                       | 3TC, TDF, NVP               |
| 22    | 15             | 15                   | >100,000                  | AZT, ABC, 3TC, ETV, RGV     |
| 23    | 179            | 139                  | 900                       | TDF, ABC, 3TC, ETV, RGV     |
| 24    | 703            | 100                  | <50                       | FTC, TDF, NVP               |
| 25    | 250            | 89                   | 350                       | TDF, FTC, NVP               |
| 26    | 802            | 376                  | <50                       | AZT, 3TC, NVP               |
| 27    | 172            | 40                   | <50                       | AZT, 3TC, NVP               |

$^1$3TC: lamivudine, ABC: abacavir, ATV: atazanavir, AZT: zidovudine, D4T: stavudine, DRV: darunavir, EFV: efavirenz, ETV: etravirine, FPV: fosamprenavir, FTC: emtricitabine, LPV: lopinavir, NVP: nevirapine, RGV: raltegravir, RTV: ritonavir, T20: enfuvirtide, TDF: tenofovir.

doi:10.1371/journal.pone.0009643.t001

Figure 2. FcRγ expression in monocytes of HIV-infected and uninfected individuals. FcRγ mRNA (A) and protein (B) were determined by Q-PCR and quantitative infrared immunoblotting in extracts from monocytes purified by FACS from blood of HIV-1 infected (individuals 1–18, Table 1) and control subjects. Fluorescence from FcRγ immunoblots measured at 680 nm was normalised to fluorescence of GAPDH in the same immunoblots, measured at 800 nm. FcRγ mRNA was determined from real-time PCR measurements using the comparative threshold method with GAPDH mRNA serving as internal control. Differences between groups were tested using the Mann-Whitney U test for non-parametric data, with a value <0.05 assumed to be significant. Horizontal bars represent median values.

doi:10.1371/journal.pone.0009643.g002
correlation between FcR expression and NK cell frequency in HIV-uninfected subjects at both mRNA and protein levels ($r^2 = 5 \times 10^{-5}, r^2 = 0.024, p = 0.71$, respectively). In this group of patients, therefore, decreased FcR expression is principally found in HIV-1-infected individuals with preserved NK cell numbers. It is not likely that decreased FcR expression is due to a shift in the proportion of CD56dim CD16+ NK and CD56bright CD16- cell subsets since both subsets express similar levels of FcR (Figure 1E).

**Discussion**

We have shown that FcR mRNA and protein expression in HIV-infected individuals receiving cART is decreased in CD56+/CD94+ lymphocytes in which the major FcR-expressing cells are NK cells, but are not decreased in monocytes. We confirmed that the decrease occurs in NK cells using cells purified from a second group of patients also receiving cART. Decreased FcR expression was due to loss of FcR expression at a single cell level, and not due to depletion of FcR-expressing NK cells, or altered proportions of NK cell subsets within the CD56+/CD94+ population of our cohort of HIV-infected individuals. FcR protein expression within monocytes is not altered, suggesting that the defect in ITAM protein expression is specific for FcR in NK cells. This is also suggested by the observation that TCR mRNA levels were not decreased in either T lymphocytes or NK cells purified from these individuals. This is the first report of expression of the important ITAM signalling protein FcR in peripheral blood mononuclear cells from patients with HIV-1 infection or, to our knowledge, any viral infection.

Since FcR expression in human immune cells is not well documented, it was initially measured in monocytes, T lymphocytes and CD56+/CD94+ lymphocytes obtained from uninfected individuals and showed high levels of expression of both mRNA and protein in monocytes and CD56+/CD94+ lymphocytes. Within the CD56+/CD94+ lymphocytes population, FcR was only detected in NK cells but not in CD56+/CD94-expressing T lymphocytes (Figure 1). This observation suggests that FcR
expression detected in CD56\(^+/\)CD94\(^+\) lymphocytes was due to FcR\(\gamma\)-expressing NK cells. Given that FcR\(\gamma\) also acts as a chaperone and is required for CD16 surface expression [19,20,21,22], the levels of FcR\(\gamma\) in CD56\(^{\text{dim}}\) CD16\(^{+}\) and CD56\(^{\text{bright}}\) CD16\(^{+}\) NK cell subsets were compared. FcR\(\gamma\) mRNA expression in CD56\(^{\text{dim}}\) CD16\(^{+}\) and CD56\(^{\text{bright}}\) CD16\(^{+}\) NK cell subsets were however similar, which suggests that FcR\(\gamma\) levels are not limiting CD16 surface expression in the latter population. To our knowledge, this is the first study to investigate FcR\(\gamma\) expression in NK cell subsets. Our data also show that there is little or no FcR\(\gamma\) expression in T lymphocytes compared to monocytes and CD56\(^+/\)CD94\(^+\) lymphocytes in either HIV-1-infected or uninfected individuals (data not shown).

In a limited number of patients, we observed an increase in FcR\(\gamma\) mRNA expression in monocytes relative to HIV-uninfected subjects. This was not observed however with FcR\(\gamma\) protein levels, which were similar to those of uninfected individuals. The significance of increased FcR\(\gamma\) mRNA levels in monocytes from HIV-1-infected individuals is unclear and will need to be confirmed in a larger cohort of patients. In contrast to monocytes, we observed a significant decrease in FcR\(\gamma\) mRNA and protein expression in CD56\(^{\text{dim}}\)/CD94\(^+\) lymphocytes of HIV-infected individuals. Our data demonstrate that decreased FcR\(\gamma\) mRNA expression was strongly and significantly correlated with decreased FcR\(\gamma\) protein expression within the mixed CD56\(^{\text{dim}}\)/CD94\(^+\) lymphocyte population isolated from HIV-1-infected individuals. We did not observe any significant correlation of defective FcR\(\gamma\) mRNA and protein with nadir or current CD4 counts. This contrasts with the previous reports on the effect of HIV-1 infection on TCR\(\sigma\) expression in patients not receiving cART in which there was a correlation with CD4 counts and an inverse correlation with viral loads [10,11,23]. Since only NK cells within this population express FcR\(\gamma\), we considered whether FcR\(\gamma\) depletion within CD56\(^{\text{dim}}\)/CD94\(^+\) lymphocytes may be caused by the loss of FcR\(\gamma\)-expressing NK cells. However, there was no correlation between decreased FcR\(\gamma\) mRNA or protein levels and the proportion of NK cells within the sorted CD56\(^{\text{dim}}\)/CD94\(^+\) populations analysed (data not shown). This shows that decreased FcR\(\gamma\) levels in CD56\(^{\text{dim}}\)/CD94\(^+\) population is more likely due to loss of FcR\(\gamma\) expression within NK cells. We confirmed this by measuring FcR\(\gamma\) expression in purified NK cells from additional patients and control subjects. FcR\(\gamma\) mRNA levels were not significantly decreased in NK cells from these additional patients. When we investigated the expression of FcR\(\gamma\) as a function of age within the HIV-uninfected donors there was no correlation at either the protein \(r^2 = 0.055, p = 0.34\) or the mRNA level \(r^2 = 0.015, p = 0.63\). The difference between in FcR\(\gamma\) expression between HIV-infected and uninfected subjects is therefore not due to differences in age. Analysis of NK cells from a larger numbers of patients is required to determine whether decreased FcR\(\gamma\) mRNA...
occurs in patients receiving cART. Our ongoing study is currently addressing this.

Several studies have shown that the proportion of NK cell subsets is altered during chronic HIV-1 infection, with loss of CD56dim CD16+ NK cell subsets [17,24,25,26]. However, in HIV-1 infection where viral replication is well-controlled, the proportion of these subsets is similar to that of uninfected individuals [17,24]. Since the majority of HIV-1-infected individuals in our cohort had undetectable viral loads and we show that both CD56dim CD16+ and CD56bright CD16− NK cells expressed equal levels of FcγRI, alterations in the proportion of these subsets are unlikely to account for the FcγRI depletion observed in our study. Taking all of these observations together, our results indicate that decreased FcγRI levels are likely to be due to loss of FcγRI expression within FcγRI-expressing NK cells.

The potential mechanisms underlying defective FcγRI transcription within NK cells are unclear, as FcγRI transcriptional regulation is poorly understood. Recently however, Juang and colleagues reported that Elf-1, a member of the Ets family of transcription factors, is a negative transcriptional regulator of FcγRI in human T lymphocytes whereas it is a positive transcriptional regulator for TCRcRε in the same cells [27,28]. Neither the role of Elf-1 in FcγRI expression in NK cells nor the effect of HIV-1 infection on Elf-1 expression is known. Given the reciprocal effects of Elf-1 on FcγRI and TCRcRε expression, and since we did not observe increased TCRcRε expression in both CD56−/CD94+ lymphocytes and NK cells, we consider this an unlikely mechanism for decreased FcγRI expression.

A limitation of this study is the lack of patients with detectable viremia to enable a correlation of FcγRI expression with viral load to be performed. This was due, in part, to the difficulty in isolating sufficient NK cells from HIV patients with high viral loads to allow biochemical analysis of FcγRI protein levels. This is due to the low numbers of NK cells in such individuals [17]. Firstly, although the sample size was small, the decrease in FcγRI expression in NK cells attained statistical significance and was observed in two groups of patients in CD56−/CD94+ lymphocytes and in highly purified NK cells. This highlights the reproducible nature of the observed decrease of FcγRI expression even in patients with undetectable viral load. The cross-sectional study described herein needs to be extended with a longitudinal study to determine the relationship between cART and restoration of TCRcRε expression in T cells and NK cells, and the effect of cART on FcγRI expression in monocytes and NK cells.

The reason why FcγRI expression decreases in NK cells but not monocytes is not clear. Neither cell type is infected by HIV-1 to an appreciable extent, and changes in FcγRI expression reflect a bystander mechanism. A possible explanation is that NK cells respond more than monocytes to a soluble factor, such as a cytokine, responsible for these changes. We have demonstrated that HIV-1-infection of monocyte-derived macrophages in vitro leads to defective FcγRI-mediated phagocytosis through a bystander mechanism which was associated with FcγRI protein depletion [16]. Therefore it is of interest to investigate soluble factors that mediate FcγRI suppression in NK cells, such as TGF-β1 [29,30]. Alternatively, if changes in FcγRI expression are due to persistent immune activation it would be relevant to correlate loss of FcγRI with plasma endotoxin levels and markers of immune activation such as HLA-DR and CD38 expression.

Our finding that FcγRI is reduced in chronically-infected HIV-infected persons receiving cART suggests that ITAM signalling and function of the NK cell population is defective in the setting of treatment with cART. It is known that elevated plasma endotoxin levels and immune activation are not fully normalised by cART, therefore it is possible that these are linked to aberrant NK cell ITAM signalling and function.

Acknowledgments

We thank the HIV-1 infected and control subjects who donated blood for participating in this study and the Infectious Diseases Clinical Research Unit nursing staff at The Alfred Hospital, for their help in patient recruitment.

Author Contributions

Conceived and designed the experiments: EL SMC AJ. Performed the experiments: EL JZ GP. Analyzed the data: EL JZ GP AJ. Contributed reagents/materials/analysis tools: SRL. Wrote the paper: EL SRL SMC AJ.

References

1. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, et al. (1990) The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322: 166–172.
2. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus infection after 6 years of antiretroviral therapy despite suppression of viral load. J Infect Dis 180: 649–658.
3. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365–1371.
4. Hunt PW, Marlin JN, Sinclair E, Brecht B, Hagos E, et al. (2003) Circulating CD8 T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. J Infect Dis 187: 1534–1545.
5. Solomon A, Cameron PU, Bailey M, Dunne AL, Crowe SM, et al. (2003) Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis 187: 1915–1923.
6. French MA, King MS, Tschampa JM, da Silva BA, Landay AL (2009) Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 200: 1212–1215.
7. Guadalupe M, Reay E, Sankaran S, Prindiville T, Hamm J, et al. (2003) Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77: 11708–11717.
8. Mehdra S, Poles MA, Temnen-Rac K, Horozvits A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761–770.
9. Baniyah M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4: 675–687.
10. Geertsma MF, van Wengen-Steenvraden A, van Dam EM, Ribberg K, Kroon FP, et al. (1999) Decreased expression of zeta molecules by T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. J Infect Dis 180: 649–658.
11. Trimble LA, Lieberman J (1998) Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and down-modulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 91: 585–594.
12. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J (2000) Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3ζeta and CD28, key signaling molecules for T-cell activation. J Virol 74: 7320–7330.
13. Altschuler CL, Lowell CA (2007) The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE 2007: re2.
14. Arase N, Arase H, Park SY, Ohno H, Ra C, et al. (1997) Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 186: 1957–1963.
15. Kedzierska K, Ellery P, Mak J, Lewin SR, Crowe SM, et al. (2002) HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. J Immunol 168: 2905–2903.
16. Lecanoyah E, Wines BD, Crowe SM, Johosowsky A (2007) The mechanism underlying defective Fcgamma receptor-mediated phagocytosis by HIV-1-infected human monocyte-derived macrophages. J Immunol 178: 1096–1104.
17. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, et al. (2005) Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106: 3366–3369.

18. Alter G, Malenfant JM, Delabre RM, Yu XG, et al. (2004) Increased natural killer cell activity in viremic HIV-1 infection. J Immunol 173: 5305–5311.

19. Arase H, Suenaga T, Arase N, Kimura Y, Ito K, et al. (2001) Negative regulation of expression and function of Fc gamma RIII by CD5 zeta in murine NK cells. J Immunol 166: 21–25.

20. Hibbs ML, Selvaraj P, Carpen O, Springer TA, Kuster H, et al. (1989) Mechanisms for regulating expression of membrane isoforms of Fc gamma RIICD16. Science 246: 1608–1611.

21. Park SY, Ueda S, Ohno H, Hamano Y, Tanaka M, et al. (1998) Resistance of Fc receptor− deficient mice to fatal glomerulonephritis. J Clin Invest 102: 1229–1238.

22. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV (1994) FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76: 519–529.

23. Geertsma MF, Stevenhagen A, van Dam EM, Nibbering PH (1999) Expression of zeta molecules is decreased in NK cells from HIV-infected patients. FEMS Immunol Med Microbiol 26: 249–257.

24. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, et al. (2003) Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 100: 15011–15016.

25. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, et al. (2005) Characterization of CD56−/low natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 102: 2896–2891.

26. Tarazona R, Casado JG, Delarosa O, Torre-Cisneros J, Villanueva JL, et al. (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22: 176–183.

27. Rellahan BL, Jensen JP, Howcroft TK, Singer DS, Benveni E, et al. (1998) Elf-1 regulates basal expression from the T cell antigen receptor zeta-chain gene promoter. J Immunol 160: 2794–2799.

28. Juang YT, Sumibcay L, Toltay M, Wang Y, Kyttaris VC, et al. (2007) Elf-1 binds to GGAA elements on the FcRgamma promoter and represses its expression. J Immunol 179: 4084–4089.

29. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, et al. (2003) TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol 174: 5987–5993.

30. Trindadapane S, Wardrop R, Baran CP, Wang Y, Opalek JM, et al. (2003) TGF-beta 1 Supresses Myeloid Fc(gamma) Receptor Function by Regulating the Expression and Function of the Common (gamma)-Subunit. J Immunol 170: 4572–4577.
Author/s:
Leeansyah, E; Zhou, J; Paukovics, G; Lewin, SR; Crowe, SM; Jaworowski, A

Title:
Decreased NK Cell FcR gamma in HIV-1 Infected Individuals Receiving Combination Antiretroviral Therapy: a Cross Sectional Study

Date:
2010-03-10

Citation:
Leeansyah, E; Zhou, J; Paukovics, G; Lewin, SR; Crowe, SM; Jaworowski, A, Decreased NK Cell FcR gamma in HIV-1 Infected Individuals Receiving Combination Antiretroviral Therapy: a Cross Sectional Study, PLOS ONE, 2010, 5 (3)

Persistent Link:
http://hdl.handle.net/11343/57241

File Description:
Published version